Corrigendum

Corrigendum Corrigendum (1642) Total Article Views Authors: Skibinski G, Finkbeiner S Published Date September 2011 Volume 2011:2 Pages 27 - 28 DOI: http://dx.doi.org/10.2147/IJHTS.S23958 Finkbeiner S, Skibinski G. Drug discovery in Parkinson's disease: update and developments in the use of cellular models. International Journal of High Throughput Screening. 2011:2 15-25. The authors' affiliations should be as displayed below. Gaia Skibinski1,2 Steven Finkbeiner1,2,3,4 1Gladstone Institute of Neurological Disease, 2Taube-Koret Center for Huntington's Disease Research, the Consortium for Frontotemporal Dementia Research, and the Hellman Family Foundation Program for Alzheimer's Disease Research, 3Graduate Programs in Biomedical Sciences and Neuroscience, University of California, 4Departments of Neurology and Physiology, University of California, San Francisco, California, USA Original Article Post to: Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter Other articles by Dr Steve Finkbeiner Drug discovery in Parkinson's disease: update and developments in the use of cellular models Readers of this article also read: Performance in L1 and L2 observed in Arabic-Hebrew bilingual aphasic following brain tumor: A case constitutes double dissociation Local anesthetic failure associated with inflammation: verification of the acidosis mechanism and the hypothetic participation of inflammatory peroxynitrite Alogliptin: a new addition to the class of DPP-4 inhibitors Morgellons disease: Analysis of a population with clinically confirmed microscopic subcutaneous fibers of unknown etiology Neurotransmitter testing of the urine: a comprehensive analysis Epigenomics in cancer management Intercellular cancer collisions generate an ejected crystal comet tail effect with fractal interface embryoid body reassembly transformation Fungus-mediated biological synthesis of gold nanoparticles: potential in detection of liver cancer Chronic eosinophilic pneumonia due to radiographic contrast administration: an orphan disease? Dabrafenib and its potential for the treatment of metastatic melanoma